HLX91-048-based ADC / Fosun Pharma - LARVOL DELTA

Discovery of a novel antibody-drug conjugate linker-payload with a distinct killing mechanism via prolonged unfolded protein response activation (AACR 2025) - "We reported a first-in-class ADC linker-payload featuring a highly differentiated killing mechanism that demonstrated exceptional efficacy and safety in preclinical evaluations. Preliminary toxicology studies in non-human primates have been scheduled."

Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER